Osteonecrosis of the femoral head is a recalcitrant and paralyzing disease often discovered in the end stage at the time of diagnosis, which is often performed by physical examination and diagnostic imaging. Osteonecrosis of the femoral head is typically caused by trauma or long-term steroid use. There are over 30 million patients in the US taking steroids, and roughly 40% will develop osteonecrosis of the femoral head. However, the exact pathophysiological process is not well understood. This study aims to examine the alteration in serum glycosylation of osteonecrosis of the femoral head using the state-of-the-art analytical tools to provide more chemical data for pathophysiology research and possibly biomarker discovery. A training set containing 27 serum samples from steroid-induced osteonecrosis of the femoral head patients and 25 from gender-and age-matched controls was collected and analyzed. Glycosylation of whole serum and site-specific glycosylation of immunoglobulins are characterized using electrospray ionization-Q-time of flight and electrospray ionization-Triple-Quadruple via multiple reaction monitoring, respectively. The whole serum glycosylation analysis yielded 14 Nglycan compositions and multiple reaction monitoring yielded eight glycopeptides that were altered between cases and controls with statistical significance. The increase of nonsialylated, nonfucosylated N-glycans and decrease of fucosylated Nglycans are associated with the development of osteonecrosis of the femoral head. Glycosylation is a posttranslational protein modification and is apparently affected by osteonecrosis of the femoral head. Future studies with a larger cohort and patients from earlier stage will be performed to assess these potential markers' value in disease onset.
Introduction
Nontraumatic osteonecrosis of the femoral head (ONFH) is a common and devastating disease that primarily affects patients in the third to fifth decades of their life. In the United States, 10,000-20,000 new cases are diagnosed every year, and around 200,000 new cases occur in China. [1] [2] [3] ONFH accounts for 5-12% of total hip arthroplasties (THAs) each year in the United States. 4 Steroid-induced ONFH (SONFH) is believed to account for a high percentage of nontraumatic ONFH. 5 Nagasawa et al. 6 found that 33% of patients with systemic lupus erythematosus progressed to ONFH after receiving steroid treatment. Vascular collapse and necrosis resulting from pressure increase in the femoral head due to adipocytes hypertrophy and vascular occlusion due to fat embolism are the two proposed mechanisms for SONFH. However, the exact pathophysiological process of SONFH is still not well understood. 7 Steinberg 8 classification is a commonly used system to evaluate the disease progression based on radiographic change including stage 0, I, II, III, IV, V, and VI. Conservative treatments, both surgical and nonsurgical, can preserve the femoral head in early stages while a replacement of the hip joint is needed in late stages. A study shows a success rate of 86, 61, and 59% by conservative treatment in Steinberg stage I, II, and III, respectively. 9 Currently, magnetic resonance imaging (MRI) is believed to be effective in diagnosing ONFH by providing information on arthritic morphological changes. Unfortunately, MRI is very expensive and time consuming and not useful in assessing the effectiveness of treatment. 10, 11 Early detection is critical in order to possibly prevent and delay the progression of the disease and avoid the eventual THAs. Therefore, a less cumbersome, less intrusive but more efficient method is needed to observe and monitor the onset and pathological progression of ONFH. There have been biomarker studies reported for ONFH. Measurement of interleukin 33 and adiponectin using enzyme-linked immunosorbent assay method showed a significantly higher level of interleukin 33 in ONFH III/IV compared to I/II and a significantly lower level of adiponectin in ONFH compared to healthy controls; however, sensitivity and specificity were not evaluated. 12, 13 Glycosylation is a posttranslational modification of proteins that is common and abundant in blood and has been shown to vary with various pathological disease states. [14] [15] [16] [17] [18] [19] [20] [21] [22] Significant improvements in glycomic and glycoproteomic methods have made it possible to identify and quantitate hundreds of glycoforms simultaneously. [23] [24] [25] [26] [27] The N-glycan analyses of human serum have also been reported using hydrophilic interaction liquid chromatography (HILIC). [28] [29] [30] [31] While these methods differ from that proposed here, they report many of the same structures that we have found in previous studies 32 and in the current study. 31 (Saldova et al.) The most abundant N-glycan composition in healthy controls is consistent with our result which is A2G2S2 (structure naming described in online supporting information) corresponding to N5402 in our study. The other major peaks in a HILIC chromatogram of serum N-glycans in the study from Gornik et al. 31 contain A2G2S1 corresponding to N5401, A3F1G3S3 corresponding to N6513, A1G1 corresponding to N3300 which are all observed in this study. However, those glycans are reported with slightly lower abundances both in this study and the study by Saldova et al. 29 Cause of the difference is likely coming from the experimental settings, the separation mechanisms, and the detectors. In healthy individuals, the glycomic pattern is highly reproducible with relatively small variations. 33 Thus, the serum glycomic profile has been the focus of several efforts in disease diagnosis, monitoring progression and pathogenesis. 15, [34] [35] [36] [37] Indeed, the glycomic signature has been shown to be altered in many diseases including many types of cancers, rheumatoid arthritis, and HIV. 38, 39 There has been no glycomic analysis reported to monitor ONFH. However as a systemic disease, it is expected to similarly alter the patients' glycosylation. In this study, we mapped the serum glycomic pattern of SONFH (glucocorticoid induced) stage VI patients and compared them to age-and gender-matched healthy controls. The comprehensive serum glycomic map includes two types of analysis, namely profiling of released N-glycans using a microfluidic chip nano-LC system coupled to a time of flight (TOF) mass spectrometer (MS) and site-specific immunoglobulin (Ig) glycoform monitoring using an ultra-performance liquid chromatography (UPLC) with a triple quadrupole (QqQ) MS. 40, 41 This comprehensive serum glycomic analysis reveals serum glycans that can potentially be used as markers for the disease and may be of value toward understanding the pathological mechanism.
Results
The glycosylation of ONFH patient serum was investigated for its potential as a biomarker. Two methods were employed for the glycomic analysis. First, a comprehensive profile was obtained yielding over 300 serum N-glycans. Identifications were based on searching the accurate masses against a combination of a theoretical and experimental database developed previously. 42 The database contains nearly 500 compositions. Second, site-specific glycoforms on IgG, IgA, and IgM, the three major Igs in serum, were monitored using multiple reaction monitoring (MRM). The latter is an emerging technique that has been recently reviewed for its value in clinical practice. 17, 43 The results represent the first serum glycan profile and site-specific glycoform determination of proteins for ONFH. Statistical tools including two-tailed unpaired t-test, partial least squares (PLS), and receiver operating characteristic (ROC) were used to evaluate the significance of the alteration, classification power, and sensitivity and specificity, respectively. Fourteen N-glycan compositions are significantly changed between the control and ONFH groups. Eight site-specific N-glycan compositions are also significantly altered. Seven of the eight significant site-specific N-glycans do not show significant change in the released form, as the glycans may originate from many other proteins, thereby indicating the value of site-specific analysis.
Clinical samples and randomization
The sample information is summarized in Table 1 . Each group was age and gender matched. Samples were randomized before sample preparation and analysis. One commercial standard human serum sample was inserted every 10 randomized samples to monitor the sample preparation and instrument reproducibility.
Serum N-glycan profiling using nanoLC-Chip-TOF Global serum N-glycomic profiles were acquired using nanoLC-Chip-TOF MS. N-glycans are separated on a porous graphitized carbon (PGC) column and detected by a TOF mass analyzer. Figure 1 shows a representative total compound chromatogram for the ONFH and control groups. Each peak represents a distinct N-glycan structure. Abundances are calculated by integrating the ion count associated with each chromatographic peak. Relative abundances are obtained by normalizing the abundance of each N-glycan to the total N-glycan abundance. All comparisons were made based on relative abundances.
N-glycans may be subdivided into several classes based on specific structural features: sialylated complex/hybrid (CH-S), fucosylated complex/hybrid (CH-F), sialylated fucosylated complex/hybrid (CH-FS), high mannose (HM), and nonsialylated, nonfucosylated complex/hybrid (CH). Examination of the relative abundance of each N-glycan subclass indicates that CH-type glycans are up-regulated 20.1% significantly with a P value of 0.0018 while CH-F-type glycans are down-regulated 8.4% significantly with a P value of 0.0055 in the ONFH group ( Figure 2 ). No significant differences were observed for the CH-S, CH-FS, and HM subclasses between the two groups. The relatively small error bars in Figure 2 representing the standard deviation indicate limited variation between the individuals for each subclass.
Assessment of released N-glycans as diagnostic markers
To determine the differentiating potential of the individual released N-glycans, t-test and ROC curve analyses were performed. A ROC curve was constructed based on the regression of the relative abundances to sex and age. Over 330 N-glycan compositions were searched, and over 140 N-glycan compositions were observed. However, only 58 compositions were observed in over 75% of the samples (Supporting Table S1 ). Each composition is observed to have between one and five isomers to yield over 300 unique N-glycans throughout all samples. 29, 32, 44 Table 2 shows the number of N-glycans that changed in ONFH with significant P values along with the area under the curve of ROC analysis (AUC), fold change, P value, and structure. The remainder of the monitored N-glycans is listed in Supporting Table S2 . There are 14 N-glycan compositions with statistically significant P values, 10 of which have AUC values greater than 0.7, making these potential biomarker candidates ( Table 2) . The compounds N3300, N3400, N3500, N4500, N4501, N5401, N5500, N5501, N5512, N9200 (N: N-glycan, four digits: Hex-HexNAc-Fuc-NeuAc, Hex: hexose, HexNAc: N-acetylhexoseamine, Fuc: fucose, NeuAc: N-acetylneuraminic acid) are found to be up-regulated in ONFH between 9 and 116%, with most around 50%. The compounds N3310, N4310, N4410, and N5410 are down-regulated in ONFH by 17, 23, 25, and 28%, respectively. These results are consistent with the results obtained when only the N-glycan subclasses are considered. All N-glycans down-regulated are fucosylated, while most up-regulated glycans are complex/hybrid structures. The N-glycan that was most changed is N5501, which doubled in ONFH (fold change 2.16) with an AUC of 0.72. The compound N5410, the fucosylated di-galactosylated structure decreased 28% in ONFH and yielded the largest AUC (0.85). A previous study on the association of serum glycosylation and medication by Rudd et al. 45 indicates that N5410, N5510, and N4411 decreased in the group taking glucocorticoids (P ¼ 0.0167), however did not look at ONFH patients. 19 In this study, all individuals with ONFH stopped glucocorticoid treatment 6-9 months before sample collection making it unlikely that the drug is still present in the subjects. To further investigate the relationship between the drug and the glycans, we compared the two groups with and without prior glucocorticoid regimen. In this analysis, N5410 decreased 28% (P < 0.0001), while N5510 and N4411 did not change significantly. Their results may be indications of immediate and long-term effects of the treatment on serum glycans.
Site-specific N-glycoforms of Ig
Igs G, A, and M are the most abundant glycoproteins in human serum and are associated with adaptive immune response. 33 N-glycosylation is known to have both profound and subtle effects on immune responses. 33, [45] [46] [47] [48] Therefore, we monitored the N-glycans on specific glycosylation sites of Ig A, G, and M to add to the global N-glycan analysis. 49 The glycoform and glyco-sites monitored in this work were chosen based on a previous comprehensive glycosite mapping of human serum. The MRM transitions used in this study are exactly the same and provided more comprehensively in two previous publications. 50, 51 Upon tryptic digestion, glycopeptides were analyzed by QqQ mass spectrometry using the MRM approach. The sensitivity and specificity of QqQ enabled the detection of less abundant glycopeptides (compared to peptides) in the complex serum tryptic digests. Moreover, the accuracy of its quantitation makes it a promising method in biomarker discovery. The relative abundance of each glycoform was obtained by normalizing the glycopeptide response to the peptide response of the glycoprotein as described previously. 41 Differentially expressed glycopeptides in serum of ONFH patients were evaluated using a t-test, and the classification power was evaluated using ROC curves. Ig glycopeptides with significant P values (smaller than 0.05) are listed along with the AUC, fold change, and structures in Table 3 . The remainder of the monitored glycopeptides is listed in Supporting Table S3 . Eleven N-glycan compositions were monitored for the IgG1 subclass. Ten N-glycan compositions were monitored for the IgG2 subclass. Six N-glycan compositions were monitored for the IgG3 and 4 subclasses. All glycoforms on IgG reported in a previous IgG glycan mapping study were observed in this study. 50, 51 The abundances of each IgG subclass and total IgG were also measured. The results show that the IgG subclasses and the total absolute abundances of IgG remained unchanged between the ONFH and control groups (Supporting Table S3 ). However, there were important changes in glycosylation. The compounds N5510 and N5411 on IgG1 and N4410 on IgG3 and 4 were downregulated with P values of 0.0478, 0.0366, and 0.0392, respectively (fold change 0.817, 0.804, and 0.735, respectively). However, the analysis of the corresponding released glycans N5510 and N5411 in serum were not significantly altered (Supporting Table S2 ) between the two patient groups. The results are not totally unexpected as there are many other proteins that can be a potential source for these two glycans. The N-glycan N4410 on IgG3 and 4 was down-regulated 26.5% as in accordance with 25.3% decrease of the liberated glycan in serum (P ¼ 0.039 and 0.0004, respectively). Interestingly, N4410 on IgG1 and IgG2 did not change significantly between the patient groups, suggesting differential behavior among the same glycan compositions with different protein subclasses. Compounds N3410 and N4400 on IgG2 were up-regulated significantly with P values of 0.0352 and 0.0252, and fold changes of 0.708 and 0.640, respectively, but remained unchanged in serum (Table 3) . A decrease of fucosylation on IgG1 was correlated with a stronger binding affinity to Fc gamma receptor IIIa on natural killer cells thereby increasing the antibody-dependent, cell-mediated cytotoxicity (ADCC) effect. 52, 53 In this study, the fucosylated N-glycan N5411 and N5510 on IgG1 were down-regulated significantly (fold change 0.804 and 0.817, respectively) indicating that the ADCC of IgG1 in ONFH may be induced to a higher level compared to the control group.
Nine N-glycan compositions were monitored for site 144 of IgA. This tryptic peptide is the same for IgA1 and IgA2. Eight N-glycan compositions were monitored for site 205 of IgA2 (Table 3, Supporting Table  S3 ). Six N-glycan compositions were monitored for IgM site 46 along with four N-glycan compositions for IgM site 209, five N-glycan compositions for IgM site 439, and three N-glycan compositions for the J chain (Table 3, Supporting Table S3 ). The absolute protein abundances of IgA and the relative abundances of the subclasses were also measured. IgA1 was significantly up-regulated 44.3% in the ONFH group while IgA2 did not change significantly. Consequently, total IgA protein was up-regulated significantly in the ONFH group. N-glycans N5400 and N5401 on IgA site 144 were both down-regulated significantly with P values of 0.0016 and 0.0037, respectively, and fold change of 0.757 and 0.903, respectively. J chain and IgM protein levels were not altered in ONFH serum. The glycan N4511 on site 209 of IgM was down-regulated 19.8% in the ONFH group with a P value of 0.0485, while the same composition did not change in the released glycan analysis. AUC values from ROC curves were evaluated for the site-specific N-glycans (Table 3, Supporting Table S3 ). N-glycans with both a significant P value and an AUC greater than 0.7 
Discussion
This study examined the serum glycosylation associated with ONFH to discover potential biomarkers for monitoring steroid users who are under the risk of developing ONFH. In general, we find that ONFH is associated with a general decrease in the fucosylation of serum glycoproteins. The individual glycans and the site-specific analysis, however, are more complicated but appear to yield several very promising candidate markers. Nonfucosylated glycans N4501, N4500, N3500, N5501, N5500, N3300, N3400, and N5401 are all upregulated significantly in the ONFH group in serum glycan analysis. Fucosylated glycans N5410, N4410, N4310, and N3310 are down-regulated in ONFH group, which correlates well with the increase of nonfucosylated glycans. The decrease of fucosylation further correlates with the decrease of some site-specific fucosylated glycan of Igs: N5411 and N5510 on IgG1, N4410 on IgG3&4, and N4511 on IgM site 209.
Specific glycans, namely N4501 and N3400, can differentiate the ONFH group from the control group and are both up-regulated in serum but did not change significantly in site-specific analysis of the Igs. However, their fucosylated versions (N4511 on IgM site 209, N3410 on IgG2) on the Igs can differentiate the disease. The fucosylation pathways of Igs are potentially affected by ONFH.
Leave-one-out cross validation (LOOCV) PLS regression was used to evaluate the classification power of the 10 potential N-glycan biomarkers with significant P values and AUC greater than 0.7 (Figure 3(a) ). The AUC of the 10 N-glycan classifier is 0.846 with a 0.148 false positive rate (FPR). N5410, a fucosylated N-glycan, carries a similar AUC (0.85) compared to the 10 N-glycan classifier. They both exhibit a great potential in distinguishing ONFH stage VI from healthy controls. With a prevalence of up to 40% steroid users develop ONFH, a candidate biomarker with a 0.85 ROC curve AUC value shows a promising potential warranting continuing study to give a satisfactory predictive value. 54, 55 LOOCV PLS was also used for those three site-specific N-glycans with significant P values and AUC greater than 0.7 (Figure 3(b) ). The three N-glycans together shows an AUC of 0.742, which is a smaller value compared to N5400 on IgA 144 alone. As shown in Figure 3 , the combined 10 global N-glycan classifier (Figure 3(a) ) exhibits a better separation compared to the three site-specific N-glycan classifier (Figure 3(b) ). Based on this study, it appears that the global N-glycans are more effective in distinguishing ONFH from healthy controls and therefore potentially are better biomarkers.
This study represents an early example where both whole serum N-glycosylation and site-specific Ig N-glycosylation were simultaneously examined in a clinical set. The results indicate that the two methods have complementary power in biomarker discovery. While in this case released N-glycans yielded good candidate markers, glycosylation of Igs may lead to better mechanistic understanding of the disease. It further illustrates the potential of glycans as biomarkers for diseases.
Materials and methods

Chemicals and reagents
Pooled human serum standard and human serum proteins (Ig G, Ig A, Ig M) were purchased from SigmaAldrich (St Louis, MO); peptide: N-glycosidase F (PNGase F) was obtained from New England Biolabs (Ipswich, MA); sequencing grade modified trypsin, porcine was purchased from Promega (Madison, WI); sodium borohydride was purchased from SigmaAldrich (St Louis, MO). All solvents used are of analytical or HPLC grade.
Clinical sample collection
The blood samples were collected from patients and healthy controls under approval by the Research Ethics Committee of Institute of First Affiliated Hospital of Guangzhou University of Chinese Medicine, China. Informed consent was obtained from all patients and healthy controls. All the subjects are genetically unrelated. Patients were diagnosed using anteroposterior and lateral pelvic radiographs and magnetic resonance images. SONFH was deEned by a history of a mean daily dose of !16.6 mg or highest daily dose of 80 mg of prednisolone equivalent within one year prior to the development of symptoms or radiological diagnosis in asymptomatic cases. Twentyseven glucocorticoid-induced ONFH stage VI patients and 25 healthy individuals were included in this study. The patients all stopped glucocorticoid treatment 6-9 months before sample collection. Blood fluids were drained into blood tubes without anticoagulants and allowed to clot overnight at 4 C. Subsequently, the serum was separated by centrifugation at 2000g for 15 min. The serum was aliquoted into 1.5 ml Eppendorf tubes and stored at À80 C.
N-glycan sample preparation
N-glycans were released from the serum of the ONFH group, control group, and standard serum sample using PNGase F , purified and enriched by solid phase extraction using PGC on a 96-well plate based on an established protocol. 40 The serum standard was aliquoted on the sample plate every 10 samples as the sample preparation control. The starting volume for each sample was 20 ml. Released N-glycan samples were then dried Figure 3 . (a) LOOCV PLS analysis using a classifier of 10 N-glycans with both significant P value and AUC greater than 0.7. (b) LOOCV PLS analysis using a classifier of three site-pecific N-glycans with both significant P value and AUC greater than 0.7. They are N5400 and N5401 on IgA1/2 site 144, and N3410 on IgG2 site 297, respectively. The AUC, sensitivity, specificity, FPR, and Youden index are listed. AUC: area under the curve of ROC analysis; FPR: false positive rate; ONFH: osteonecrosis of the femoral head.
and reconstituted in 50 ml deionized water for nanoLC-CHIP-TOF MS analysis.
NanoLC-Chip-TOF profiling of overall glycosylation A 1 ml solution of each reconstituted N-glycan sample was injected into an Agilent 6220 nanoLC-Chip-TOF MS for global N-glycan profiling. A standard serum N-glycan pool (obtained from the standard serum) was injected every 10 samples as the instrument control in addition to the sample preparation control standard serum. N-glycans were separated on a chip containing a PGC analytical column (particle size 5 mm, 75 mm Â 43 mm) and PGC enrichment column (particle size 5 mm, 40 nl). The 60 min binary gradient consisted of solvent A of 3% acetonitrile, 0.1% formic acid; solvent B of 90% acetonitrile, 0.1% formic acid in nanopure water (v/v) at a flow rate of 0.3 ml/min.
Glycopeptide preparation
Twenty microliters of IgG (5 mg/ml), 20 ml of IgA (1.1 mg/ml), 20 ml of IgM (1.1 mg/ml), and 2 ml of each serum sample were reduced and alkylated prior to overnight trypsin digestion in a 37 C water bath. The resulting peptide and glycopeptide mixture was directly used for QqQ MS analysis.
UPLC-electrospray ionization (ESI)-QqQ analysis of site-specific glycosylation
Ig peptides and glycopeptides were analyzed using an Agilent 1290 infinity UPLC system coupled to an Agilent 6490 ESI QqQ MS. The UPLC separation was performed on an Agilent Eclipse Plus C18 column (RRHD 1.8 mm, 2.1 Â 100 mm) capped with a Agilent Eclipse Plus C18 guard column with a 10 min binary gradient consisting of solvent A of 3% acetonitrile, 0.1% formic acid; solvent B of 90% acetonitrile, 0.1% formic acid in nano-pure water (v/v) at a flow rate of 0.5 ml/min.
Statistical analysis
Abundances of the released N-glycans were normalized to the total N-glycan abundance and abundances of site-specific N-glycans were normalized to the peptide response of the corresponding protein before statistical analysis. Glycans with a detection frequency less than 75% among either sample set were removed. The remaining unobserved values were replaced with one half of the observed minimum value of the corresponding N-glycan. The data satisfied parametric assumptions. Unpaired t-test and ROC curve analysis were applied using JMP Pro 11 (Cary, NC). LOOCV PLS regression was performed in DeviumWeb (reference: Dmitry Grapov. (2014) DeviumWeb: Dynamic Multivariate Data Analysis and Visualization Platform. v0.4).
Supporting information
Complete table of all serum glycans monitored in ONFH with fold change, P value, and AUC. Complete table of the proteins, protein subclasses, and glycopeptide monitored in ONFH with fold change, P value, and AUC.
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